Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Adaptive Biotechnologies Cor (ADPT)

298 + Investors. Track Smart Money conviction in ADPT. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +7
Streak
8Q ▲
Buyers last Q
55%

Smart Money Signals — ADPT

Based on 301 hedge funds · latest filing: 2026 Q2 · updated quarterly

📈

Buying streak — 8 quarters in a row

last 6Q
For 8 consecutive quarters, more hedge funds added ADPT than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
301 hedge funds hold ADPT right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🚀

Fast accumulation — +26% more funds vs a year ago

fund count last 6Q
+62 new funds entered over the past year (+26% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🟡

Slight buying edge — 55% buying

165 buying133 selling
Last quarter: 165 funds bought or added vs 133 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
➡️

Steady new buyers — ~54 new funds per quarter

new funds entering per quarter
Funds opening this position for the first time: 56 → 53 → 54 → 54. A stable flow of new institutional buyers suggests ongoing interest without signs of either acceleration or slowdown.
🔒

56% of holders stayed for 2+ years

■ 56% conviction (2yr+) ■ 20% medium ■ 25% new
168 out of 301 hedge funds have held ADPT for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
💰

Value +72% but shares only +9% — price-driven

Value
+71%
Shares
+8%
Last quarter: the total dollar value of institutional holdings rose +72%, but actual share count only changed +9%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.
➡️

Steady discovery — ~54 new funds/quarter

44 → 56 → 53 → 54 → 54 new funds/Q
New funds entering each quarter: 56 → 53 → 54 → 54. Consistent flow of new institutional buyers without clear acceleration or slowdown.
🏛️

Veteran-anchored — 63% veterans vs 26% newcomers

■ 63% veterans ■ 11% 1-2yr ■ 26% new
Entry-cohort mix of 306 holders: 193 (63%) are 2+ year veterans, 33 entered 1–2 years ago, and 80 (26%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
🏆

Elite ownership — 42% AUM from top-100 funds

42% from top-100 AUM funds
55 of 300 holders are among the 100 largest funds by AUM, controlling 42% of total institutional value in ADPT. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.
3.9
out of 10
Low Exit Risk
Exit risk score 3.9/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — ADPT

In 2026 Q2, 165 hedge funds were net buyers of ADPT (54 opened a new position, 111 added to an existing one), while 133 reduced or exited (86 trimmed, 47 sold completely) — a 55% buyer ratio, indicating a slight buying edge. This marks 8 consecutive quarters of net institutional buying — a persistent conviction signal. 42% of total institutional value in ADPT is held by top-100 AUM funds, reflecting elite-tier ownership quality. Net fund flow last quarter: +7 funds (more new holders than closures). Total institutional holders: 301.

Hedge Fund Ownership: ADPT

How many hedge funds hold ADPT — quarterly history vs. share price
Quarterly hedge fund ownership of ADPT vs. share price

Market Analysis: ADPT

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: ADPT

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Adaptive Biotechnologies Cor (ADPT) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much ADPT has moved relative to its sector benchmark (XLV) since the 2026 Q2 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End June 30, 2026 · 82d ago
ADPT
+33.4%
XLV
-23.8%

ADPT outperformed XLV by +57.2% since June 30, 2026.

Since 13F Filing Date August 14, 2026 · 37d ago
ADPT
+15.6%
XLV
-31.4%

Since the filing became public, ADPT outperformed XLV by +47.0% .

Interpretation: The stock has significantly outperformed its sector benchmark — the original entry opportunity has largely been captured by earlier investors. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

12 top-rated funds 2 high-conviction
Consensus
4.8
/ 10
breadth
×
Elite
1.8
/ 10
conviction
Hedge Fund Positioning: ADPT
298 + Investors

Track Smart Money conviction in ADPT. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q2) Prior (2026 Q1) Change
Funds Holding 298 294 1.36%
13F Shares 165M 152M 8.78%
Total Value $3.45B $2.01B 71.6%
New Positions 53 54 -1
Increased Positions 110 103 +7
Closed Positions 48 39 +9
Reduced Positions 84 91 -7
Total Calls 5 3 66.67%
Total Puts 1 1 -
PUT/CALL Ratio 0.2 0.33 Bullish

Statistics: ADPT

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q2)

298 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in ADPT. Verified SEC 13F-HR filings.

QUARTER:
Top 25 ADPT holders by conviction (% of portfolio weight) — 2026 Q2 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Blue Water Life Science Advisors, LP 13.65% 1,010,145 $21.7M
2 1492 Capital Management LLC 2.42% 382,840 $8.2M
3 Viking Global Investors LP 1.83% 29,993,708 $643.4M
4 Aristotle Atlantic Partners, LLC 1.64% 1,838,513 $39.4M
5 Lisanti Capital Growth, LLC 1.53% 325,155 $7.0M
6 Essex Investment Management Co LLC 1.33% 472,763 $10.1M
7 Parkman Healthcare Partners LLC 1.07% 486,984 $10.4M
8 Affinity Wealth Management LLC 0.95% 342,569 $7.3M
9 Granite Investment Partners, LLC 0.83% 757,217 $16.2M
10 Next Century Growth Investors LLC 0.69% 609,830 $13.1M
11 Oberweis Asset Management Inc/ 0.56% 1,258,751 $27.0M
12 Legato Capital Management LLC 0.49% 273,441 $5.9M
13 Alamea Verwaltungs GmbH 0.41% 24,124 $517K
14 Perceptive Advisors LLC 0.39% 1,217,325 $26.1M
15 Amova Asset Management Americas, Inc. 0.37% 1,329,856 $28.5M
16 Hillsdale Investment Management Inc. 0.33% 684,217 $14.7M
17 Edge Wealth Management LLC 0.33% 90,000 $1.9M
18 Kennedy Capital Management LLC 0.32% 849,795 $18.2M
19 Driehaus Capital Management LLC 0.31% 2,527,703 $54.2M
20 Westfield Capital Management Co LP 0.30% 4,267,645 $91.5M
21 ARK Investment Management LLC 0.29% 2,090,306 $44.8M
22 Huntleigh Advisors, Inc. 0.28% 93,171 $2.0M
23 Peregrine Capital Management LLC 0.27% 393,095 $8.4M
24 Ares Systematic Credit Ltd 0.25% 19,359 $415K
25 Odyssean, LLC 0.24% 67,709 $1.5M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Adaptive Biotechnologies Cor (ADPT)

What does the Smart Money Trend signal show for ADPT?

Buying streak — 8 quarters in a row: For 8 consecutive quarters, more hedge funds added ADPT than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for ADPT?

Slight buying edge — 55% buying: Last quarter: 165 funds bought or added vs 133 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for ADPT holders?

Elite ownership — 42% AUM from top-100 funds: 55 of 300 holders are among the 100 largest funds by AUM, controlling 42% of total institutional value in ADPT. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held ADPT?

56% of holders stayed for 2+ years: 168 out of 301 hedge funds have held ADPT for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Adaptive Biotechnologies Cor (ADPT) following the 2026 Q2 hedge fund 13F filings?

As of today, ADPT has moved +15.6% since the 2026 Q2 13F filing date (August 14, 2026), compared to -31.4% for the XLV sector ETF — an outperformance of +47.0%. Since the quarter end (June 30, 2026), ADPT has gained +33.4% vs -23.8% for XLV. The stock has significantly outperformed its sector benchmark — the original entry opportunity has largely been captured by earlier investors.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →